Business
PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer
About this update from Pharmacyte Biotech, Inc.
[{"type":"text","content":" LAGUNA HILLS, Calif.--(BUSINESS WIRE)--\nPharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that this week’s Annual Meeting of Shareholders will be held virtually on Wednesday, June 16, 2021, at 11:00 A.M., Pacific Daylight Time at\n\nhttps://www.virtualshareholdermeeting.com/PMCB2021\n\nBy now all PharmaCyte shareholders should have received a Proxy Statement with 4 separate proposals requiring shareholders to vote on each. If a shareholder has not received a Proxy Statement, please email Investor Relations at [email protected] and a Proxy Statement will be sent to you. Shareholders can vote electronically using the information in the Proxy Statement or by calling (201) 463-8535.\n\nPharmaCyte’s Chief Executive Officer (CEO), Kenneth L. Waggoner, said of the importance of this vote prior to Wednesday’s Annual Meeting, “Each shareholder voting ‘yes’ on the proposals, especially Proposal No. 2, is critical for PharmaCyte to remain a viable company and for its pancreatic cancer treatment to remain in development and avoid being shelved. We encourage every shareholder to obtain and read the Proxy Statement and then participate in the vote.”\n\nDuring the virtual meeting, the CEO will update shareholders on the latest work being done by PharmaCyte’s assembled scientific team to address the FDA’s requests related to the clinical hold on PharmaCyte’s treatment for locally advanced inoperable pancreatic cancer. Additionally, other company business will be addressed, including a discussion on the proposals set forth in the Proxy Statement and subsequent voting.\n\nTo learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the Company’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer\n\nAbout PharmaCyte Biotech\n\nPharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology is being used as a platform upon which therapies for several types of ...